Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and to induce PD-1 receptor internalization (endocytosis ...

Novocure (NVCR) recognized first non-small cell lung cancer revenues ahead of schedule, with 92 Optune Lua prescriptions for NSCLC received in ...

Taiwan’s health authority on Thursday said it has plans to expand existing National Health Insurance (NHI) coverage to ...

Hong Kong-based biopharma company Akeso (HKEX: 9926) announced that its global first-in-class PD-1/VEGF bispecific antibody, ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...